证券研究报告 | 公司点评报告 2025 年 05 月 07 日 中直股份（600038.SH） 24 年实现营收稳增，盈利能力预计持续提升 中游制造/军工 公司实现营业收入 297.66 亿元，同比增长 11.93%，完成年度预算 97%；实现 归母净利润 5.56 亿元，同比-7.98%，完成年度预算 78%；扣非归母净利润 4.82 亿元，同比 19.68%。 2025 年财务预算：预计实现营收 302.49 亿（同比+1.63%），预计实现归母 净利润 6.04 亿（同比+8.66%），据此计算净利率预计达到 2%左右，同比提 升 0.38 pct。 ❑ 盈利预测：预计公司 2025/2026/2027 年归母净利润为 6.12/7.23/8.50 亿元， 强烈推荐（维持） 目标估值：NA 当前股价：35.83 元 基础数据 | 总股本（百万股） | 820 | | --- | --- | | 已上市流通股（百万股） | 669 | | 总市值（十亿元） | 29.4 | | 流通市值（十亿元） | 24.0 | | 每股净资产（MRQ） | 20.9 | | ROE（TTM） | 3.7 | | 资 ...

基础化工/化学制品 雅化集团（002497.SZ） Q1 利润同比大幅增长，锂精矿自给率提升在即 2025 年 05 月 07 日 投资评级：买入（维持） | 日期 | 2025/5/6 | | --- | --- | | 当前股价(元) | 11.35 | | 一年最高最低(元) | 13.93/7.98 | | 总市值(亿元) | 130.82 | | 流通市值(亿元) | 120.15 | | 总股本(亿股) | 11.53 | | 流通股本(亿股) | 10.59 | | 近 3 个月换手率(%) | 100.19 | 股价走势图 数据来源：聚源 -32% -16% 0% 16% 32% 2024-05 2024-09 2025-01 2025-05 雅化集团 沪深300 相关研究报告 《锂业+民爆"双主业"并行，未来业 绩增长可期—公司首次覆盖报告》 -2025.2.25 | 金益腾（分析师） | 蒋跨跃（分析师） | 李思佳（联系人） | | --- | --- | --- | | jinyiteng@kysec.cn | jiangkuayue@kysec.cn | lisijia@kysec. ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 华大智造(688114) | 投资评级 | 买入 | | --- | --- | | 上次评级 | 买入 | [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 测序试剂放量可期，国内+海外双轮驱 动增长 2024Q2 环比恢复增长，测序仪装机创 新高 基因测序业务稳步增长，全球化布局 持续深化 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 测序仪装机创新高，为试剂放量奠定基础 [Table_ReportDate] 2025 年 05 月 07 日 [Table_S 事件：公司发布 ummary]2024 年年报 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 36.726 billion yuan in 2024, a year-on-year increase of 5.14%, and a net profit attributable to shareholders of 11.668 billion yuan, up 0.74% year-on-year. In Q1 2025, the company achieved a revenue of 8.237 billion yuan, down 12.12% year-on-year, and a net profit of 2.629 billion yuan, down 16.81% year-on-year [4][5] - Domestic growth is under pressure, while the overseas market continues to show high growth. In 2024, domestic revenue was approximately 20.29 billion yuan, accounting for about 55.3% of total revenue, down 5.1% year-on-year. Conversely, overseas revenue was about 16.43 billion yuan, accounting for approximately 44.7%, with a year-on-year growth of about 21.3% [5][6] - The in-vitro diagnostics (IVD) segment has become the company's largest business, generating revenue of 13.765 billion yuan in 2024, a year-on-year increase of 10.82%. The international IVD business grew over 30% year-on-year [7][8] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 36.726 billion yuan, with a year-on-year growth of 5.14%. The net profit attributable to shareholders was 11.668 billion yuan, reflecting a 0.74% increase year-on-year. For Q1 2025, revenue was 8.237 billion yuan, down 12.12% year-on-year, and net profit was 2.629 billion yuan, down 16.81% year-on-year [4][5][11] Market Dynamics - Domestic revenue faced a decline due to weak hospital equipment procurement and the impact of DRG 2.0. However, recovery is expected in the domestic market by Q3 2025 due to easing fiscal constraints and the initiation of medical equipment upgrade projects [5][6] - The overseas market showed robust growth, particularly in the Asia-Pacific region, which grew nearly 40% year-on-year, and Europe, which rebounded with over 30% growth [5][6] Business Transformation - The company is accelerating its transition to a more streamlined business model, with IVD becoming the primary revenue driver. The installation of laboratory automation systems and high-speed chemical luminescence instruments has been significant, with nearly 190 systems installed in 2024 [7][8] - The company has established localized production projects in 13 countries, enhancing its international market penetration and supporting growth in the IVD segment [8][9] Future Outlook - Revenue projections for 2025-2027 are 40.928 billion yuan, 48.212 billion yuan, and 56.881 billion yuan, with expected year-on-year growth rates of 11.4%, 17.8%, and 18.0%, respectively. Net profit is projected to reach 13.203 billion yuan, 15.688 billion yuan, and 18.629 billion yuan during the same period [9][11]

华大智造（ [Table_StockNameRptType] 688114） 公司点评 2024 年收入平稳增长，国产替代加速 | [Table_Rank] | 投资评级：买入（维持） | | | --- | --- | --- | | 报告日期： | 2025-05-07 | | | [Table_BaseData] 收盘价（元） | | 81.02 | | 近 12 个月最高/最低（元） | | 106.66/ | | | | 34.68 | | 总股本（百万股） | | 417 | | 流通股本（百万股） | | 213 | | 流通股比例（%） | | 51.12 | | 总市值（亿元） | | 337 | | 流通市值（亿元） | | 173 | [公司价格与沪深 Table_Chart] 300 走势比较 -48% -16% 17% 49% 81% 5/24 8/24 11/24 2/25 5/25 华大智造 沪深300 [Table_Author] 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 分析师：李婵 执业证书号：S0010523120002 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [6][18]. Core Views - The company has seen a significant increase in overseas orders, particularly in Southeast Asia and the Middle East, contributing to a 29.25% year-on-year revenue growth in Q1 [1]. - The company is investing in perovskite solar cells to explore new growth avenues, aiming to expand its market presence in emerging markets like the Philippines and Kenya [4]. - Despite a decline in domestic business margins, the company has achieved a 93% year-on-year increase in new contracts signed in 2024 [2]. Financial Performance Summary - In Q1 2025, the company reported revenues of 372 million, a 29.25% increase year-on-year, with a net profit of 36 million, up 18.59% [1]. - For the full year 2024, the company expects revenues of 1.297 billion, a slight increase of 1.51%, but a significant drop in net profit by 46.86% to 93 million due to declining gross margins and increased costs [1][5]. - The company’s gross margin for 2024 is projected to be 29.59%, down 4.67 percentage points year-on-year, with a notable decline in Q4 2024 [2][3]. Order and Revenue Trends - The company signed new contracts worth 2.053 billion in 2024, reflecting a 93% increase compared to the previous year [2]. - Revenue from the foundation treatment and pile foundation engineering segments for 2024 is expected to be 824 million and 430 million, respectively, with the latter showing a 55.10% increase [2]. Cash Flow and Expenses - The company experienced a cash flow from operations (CFO) of -83 million in 2024, a decrease of 217 million year-on-year, but a positive CFO of 45 million in Q1 2025 [3]. - The operating expense ratio for 2024 is projected to be 17.36%, an increase of 1.62 percentage points year-on-year, primarily due to rising management costs from overseas business growth [3].

证券研究报告·公司深度研究·汽车零部件 飞龙股份（002536） 新能源热管理细分龙头，非车业务进入爆发 期 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 4,095 | 4,723 | 5,447 | 6,268 | 6,942 | | 同比（%） | 25.69 | 15.34 | 15.33 | 15.07 | 10.75 | | 归母净利润（百万元） | 261.77 | 329.62 | 454.71 | 630.84 | 788.75 | | 同比（%） | 211.14 | 25.92 | 37.95 | 38.73 | 25.03 | | EPS-最新摊薄（元/股） | 0.46 | 0.57 | 0.79 | 1.10 | 1.37 | | P/E（现价&最新摊薄） | 35.22 | 27.97 | 20.28 | 14.61 | 11.69 | [Table_Tag] [Table_Sum ...

江丰电子（300666.SZ）：双轮驱动 业绩高增，精密部件开启成长新篇 章 2025 年 5 月 6 日 推荐/维持 江丰电子 公司报告 ——2024 年报业绩点评 事件： 2025 年 4 月 15 日，江丰电子发布 2024 年度报告：公司 2024 年实现营业收 入 36.05 亿元，同比增长 38.57%；归母净利润 4.01 亿元，同比增长 56.79%； 扣非归母净利润 3.04 亿元，同比增长 94.92%。 点评： 公司 2024 年度营收同比增长 38.57%，扣非归母净利润同比增长 94.92%，业 绩超预期。2024 年，实现营业收入 36.05 亿元，同比增长 38.57% ；归母净 利润 4.01 亿元，同比增长 56.79%；扣非归母净利润 3.04 亿元，同比增长 94.92%；毛利率为 28.17%，同比减少 1.03pct。主要得益于报告期内客户订 单持续攀升，其中超高纯金属溅射靶材销售收入达 23.33 亿元，同比增长 39.51%，毛利率为 31.35%，同比提升 2.90pct；公司在全球晶圆制造溅射靶 材领域的市场份额进一步扩张，在技术和市场份额方面均跻身全球领先行 ...

丨证券研究报告丨 公司研究丨点评报告丨传音控股（688036.SH） [Table_Title] 传音控股 2024 年报及 2025 年一季报点评： 业绩短期承压，看好新兴市场拓展机遇 报告要点 [Table_Summary] 2024 年公司实现营收 687.15 亿元，同比增长 10.31%；归母净利润 55.49 亿元，同比增长 0.22%。2025Q1 公司实现营收 130.04 亿元，同比下降 25.45%；归母净利润 4.9 亿元，同比 下降 69.87%。2024 年公司毛利率 21.28%，同比下降 3.17pct；归母净利率 8.08%，同比下降 0.81pct。2025Q1 公司毛利率19.27%，同比下降2.88pct；归母净利率 3.77%，同比下降 5.55pct。 分析师及联系人 [Table_Author] %% %% research.95579.com 1 传音控股（688036.SH） cjzqdt11111 [Table_Title 传音控股 2024 2] 年报及 2025 年一季报点评： 业绩短期承压，看好新兴市场拓展机遇 [Table_Summary2] 事件描述 ...

丨证券研究报告丨 公司研究丨点评报告丨鼎龙股份（300054.SZ） [Table_Title] 鼎龙股份：半导体业务持续向好，国产替代加速 进行 报告要点 [Table_Summary] 近期公司发布 2024 年报及 2025 年一季度报告。 2024 年公司实现营收 33.38 亿元，同比增加 25.14%；实现归母净利润 5.21 亿元，同比增加 134.54%；2025Q1 公司实现营收 8.24 亿元，同比增加 16.37%；实现归母净利润 1.41 亿元， 同比增加 72.84%。 分析师及联系人 [Table_Author] 杨洋 王泽罡 SAC：S0490517070012 SAC：S0490521120001 SFC：BUW100 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 鼎龙股份（300054.SZ） cjzqdt11111 [Table_Title 鼎龙股份：半导体业务持续向好，国产替代加速 2] 进行 [Table_Rank]投资评级 买入丨维持 | 公司基础数据 | | | --- | --- | | [Table_BaseDa ...